Biopharmx (NYSEAMERICAN:BPMX) is scheduled to be announcing its earnings results on Wednesday, March 21st. Analysts expect the company to announce earnings of ($0.04) per share for the quarter.
Shares of Biopharmx (NYSEAMERICAN BPMX) opened at $0.31 on Wednesday. The stock has a market capitalization of $45.42, a price-to-earnings ratio of -1.15 and a beta of 0.43. Biopharmx has a 52 week low of $0.10 and a 52 week high of $0.90.
In other Biopharmx news, major shareholder Vivo Capital Viii, Llc sold 2,000,000 shares of the firm’s stock in a transaction on Wednesday, March 7th. The stock was sold at an average price of $0.36, for a total value of $720,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with MarketBeat.com's FREE daily email newsletter.